Comparative Pharmacology
Head-to-head clinical analysis: LOTEMAX versus LOTEMAX SM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTEMAX versus LOTEMAX SM.
LOTEMAX vs LOTEMAX SM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lotemax (loteprednol etabonate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2 activity, thereby reducing arachidonic acid release and subsequent synthesis of prostaglandins and leukotrienes.
Loteprednol etabonate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit inflammatory mediators such as prostaglandins and leukotrienes.
One drop of 0.5% ophthalmic suspension into the affected eye(s) four times daily for up to 2 weeks.
One drop of 0.5% ophthalmic suspension into the affected eye(s) 4 times daily. For severe inflammation, may be increased to one drop every hour during the first week, then taper.
None Documented
None Documented
The terminal elimination half-life is approximately 1.5–3 hours. Due to rapid clearance, systemic accumulation is minimal with topical ocular administration.
Terminal elimination half-life is approximately 8-10 hours in healthy subjects, allowing once-daily or twice-daily dosing based on severity of inflammation.
Approximately 80% of the dose is excreted in the feces via biliary elimination as parent drug and metabolites, and about 20% is excreted in the urine as metabolites.
Renal (approximately 70% as metabolites), fecal (approximately 30% as metabolites). Less than 1% excreted unchanged.
Category C
Category C
Corticosteroid (ophthalmic)
Corticosteroid (ophthalmic)